--- title: Designing More Resilient Cancer CAR-T Therapy description: This webinar discusses CAR-T cell cancer therapy, including its benefits, treatment schema, case studies involving treatment failure, and what functional assays tell us about designing CAR-T therapies with continued efficacy. image: https://go.clinicallab.com/hubfs/IsoPlexis%20webinar%20735x200-Hubspot-1.png --- ![46886\_TCL\_IsoPlexisCancerTherapies\_BANNERS\_Revised\_AV -990x200](https://go.clinicallab.com/hs-fs/hubfs/46886_TCL_IsoPlexisCancerTherapies_BANNERS_Revised_AV%20-990x200.jpg?width=990&height=200&name=46886_TCL_IsoPlexisCancerTherapies_BANNERS_Revised_AV%20-990x200.jpg "46886_TCL_IsoPlexisCancerTherapies_BANNERS_Revised_AV -990x200") If you have already registered, please check your email for the webinar link. Speaker ![David Miklos.jpg](https://go.clinicallab.com/hubfs/David%20Miklos%20200x200.png "David Miklos") David Miklos MD, PhD # Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies Chimeric antigen receptor T-cell (CAR-T) therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies. Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19 presentation on cancer cells. To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B-cell specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR T-cell that simultaneously targets CD19 and CD22. In this webinar brought to you by IsoPlexis, David Miklos will discuss recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T product quality. | ![OnDemand Video Icon](https://go.clinicallab.com/hs-fs/hubfs/LabManager/Webinars/Registration%20Pages/OnDemand%20Video%20Icon.png?width=50&name=OnDemand%20Video%20Icon.png) | **Available On Demand Now** | | --- | --- | ![](https://go.clinicallab.com/hs-fs/hubfs/Todays%20Clinical%20Lab/TodaysClinicalLab_logo-01.png?width=500&name=TodaysClinicalLab_logo-01.png) # Register Now for the On Demand Webinar ### Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies You must have Javascript and Cookies enabled to access this webcast. ## Today's Clinical Lab needs the contact information you provide us to contact you about our products and services. You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our [privacy policy by clicking here.](https://www.clinicallabmanager.com/privacy-policy)     [![TodaysClinicalLab\_logo-02](https://go.clinicallab.com/hs-fs/hubfs/Todays%20Clinical%20Lab/TodaysClinicalLab_logo-02.png?width=300&height=66&name=TodaysClinicalLab_logo-02.png)](https://clinical.labmanager.com)   Today's Clinical Lab 1000 N West Street, Suite 1200 Wilmington, DE, USA 19801 Toll Free: 888.788.0328 | Phone: 705.528.6888 Email: [privacy@clinicallab.com](mailto:privacy@clinicallab.com) ©2024 Today's Clinical Lab® All Rights Reserved [Terms Of Use](http://www.labmanager.com/terms-of-use) | [Privacy Policy](https://www.clinicallabmanager.com/privacy-policy)